Likuiditas cepet telesisbio.com (TBIO)

Telesis Bio, Inc. (TBIO) develops automated DNA synthesis systems based on proprietary technology, although the procurement of boards and reagents remains outsourced. Demand for this equipment is tied to R&D budgets, rendering the business moderately cyclical. A stable engineering workforce is maintained by the uniqueness of the projects. This price chart confirms these data, with the current indicator standing at 1.78.

The quick ratio measures the ability of Telesis Bio, Inc. (TBIO) to meet its short-term obligations using its most liquid assets, excluding slow-moving inventories. This calculation is critical for Telesis Bio, Inc. (TBIO), as demand for DNA synthesizers depends on biotech R&D cycles. The trend of the quick ratio reflects the actual cash cushion amid patent risks. A stable metric confirms the financial stability of capital and protection against a "value trap."